Clinical Guidelines
Commentary & Perspectives

Breaking the Biomarker Bottlenecks: Part 2

Industry leaders from AstraZeneca, Leica Biosystems, and Danaher share their insights on AI’s power to democratize access to precision medicine

  • By

  • February 16, 2026

  • 9 min

Share

  • 1

    AI enhances diagnostic reproducibility.

  • 2

    It provides accurate quantitative results crucial for therapy decisions.

  • 3

    AI captures more complex biological data than human pathologists.

  • 4

    Multimodal biomarkers are vital for personalized therapies.

  • 5

    Collaboration is necessary for effective patient selection strategies.

  • 6

    Regulatory clarity is essential for technology adoption.

  • 7

    Incremental steps can improve diagnostic methods.

  • 8

    Focus on patient-centered care is imperative.

Original Source(s)

Breaking the Biomarker Bottlenecks: Part 2

Industry leaders from AstraZeneca, Leica Biosystems, and Danaher share their insights on AI’s power to democratize access to precision medicine

  • February 16, 2026

  • 9 min

Related Content

From Tissue to Treatment

Optimizing biomarker testing in prostate cancer

Identifying HER2-low expression – A pathologist led slide review

Roche Tissue Diagnostics invites you to learn more about the importance of identifying each level of HER2 expression.

  • December 14, 2022

Democratizing Tumor Genomic Profiling With Tailored Content

Join Us With Agilent For Our Webinar On Democratizing Tumor Genomic Profiling. The webinar will discuss the range of available tumor genomic profiling assays (comprehensive, tumor-specific, customized) in the Agilent SureSelect Cancer product portfolio and much, much more!

  • June 26, 2024